Literature DB >> 30036236

Characteristics of State Policies Impact Health Care Delivery: An Analysis of Mammographic Dense Breast Notification and Insurance Legislation.

Michal Horný1,2,3, Michael Shwartz4,5, Richard Duszak1, Cindy L Christiansen3, Alan B Cohen4, James F Burgess3,5.   

Abstract

BACKGROUND: Increased breast tissue density may mask cancer and thus decrease the diagnostic sensitivity of mammography. A patient group advocacy led to the implementation of laws to increase the awareness of breast tissue density and to improve access to supplemental imaging in many states. Given limited evidence about best practices, variation exists in several characteristics of adopted policies.
OBJECTIVE: To identify which characteristics of state-level policies with regard to dense breast tissue were associated with increased use of downstream breast ultrasound. RESEARCH
DESIGN: This was a retrospective series of monthly cross-sections of screening mammography procedures before and after implementation of laws.
SUBJECTS: A sample of 13,481,554 screening mammography procedures extracted from the MarketScan Research database performed between 2007 and 2014 on privately insured women aged 40-64 years that resided in a state that had implemented relevant legislation during that period. MEASURES: The outcome was an indicator of whether breast ultrasound imaging followed a screening mammography procedure within 30 days. The main independent variables were policy characteristics indicators.
RESULTS: Notification of patients about issues surrounding increased breast density was associated with increased follow-up by ultrasound by 1.02 percentage points (P=0.016). Some policy characteristics such as the explicit suggestion of supplemental imaging or mandated coverage of supplemental imaging by health insurance augmented that effect. Other policy characteristics moderated the effect.
CONCLUSIONS: The heterogeneous effect of state legislation with regard to dense breast tissue on screening mammography follow-up by ultrasound may be explained by specific and unique characteristics of the approaches taken by a variety of states.

Entities:  

Mesh:

Year:  2018        PMID: 30036236     DOI: 10.1097/MLR.0000000000000967

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  6 in total

1.  Association of State Dense Breast Notification Laws With Supplemental Testing and Cancer Detection After Screening Mammography.

Authors:  Susan H Busch; Jessica R Hoag; Jenerius A Aminawung; Xiao Xu; Ilana B Richman; Pamela R Soulos; Kelly A Kyanko; Cary P Gross
Journal:  Am J Public Health       Date:  2019-03-21       Impact factor: 9.308

2.  Physician Knowledge, Attitudes, and Practices Regarding Breast Density.

Authors:  Jordonna Brown; Chloe Soukas; Jenny J Lin; Laurie Margolies; Marimer Santiago-Rivas; Lina Jandorf
Journal:  J Womens Health (Larchmt)       Date:  2019-05-07       Impact factor: 2.681

3.  Breast Cancer Screening Trials: Endpoints and Overdiagnosis.

Authors:  Ismail Jatoi; Paul F Pinsky
Journal:  J Natl Cancer Inst       Date:  2021-09-04       Impact factor: 13.506

4.  The effect of breast density on the missed lesion rate in screening digital mammography determined using an adjustable-density breast phantom tailored to Japanese women.

Authors:  Mika Yamamuro; Yoshiyuki Asai; Naomi Hashimoto; Nao Yasuda; Yoshiaki Ozaki; Kazunari Ishii; Yongbum Lee
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

5.  Availability Versus Utilization of Supplemental Breast Cancer Screening Post Passage of Breast Density Legislation.

Authors:  Mary W Marsh; Thad S Benefield; Sheila Lee; Michael Pritchard; Katie Earnhardt; Robert Agans; Louise M Henderson
Journal:  J Womens Health (Larchmt)       Date:  2020-09-22       Impact factor: 2.681

6.  Breast cancer supplemental screening: Women's knowledge and utilization in the era of dense breast legislation.

Authors:  Jenerius A Aminawung; Jessica R Hoag; Kelly A Kyanko; Xiao Xu; Ilana B Richman; Susan H Busch; Cary P Gross
Journal:  Cancer Med       Date:  2020-06-14       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.